Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Aug;47(8):2458-64.
doi: 10.1128/JCM.01863-08. Epub 2009 Jun 17.

Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia

Ameli Tropé  1 , Katrine Sjøborg, Anne Eskild, Kate Cuschieri, Tormod Eriksen, Steinar Thoresen, Martin Steinbakk, Vigdis Laurak, Christine M Jonassen, Unni Westerhagen, Morten B Jacobsen, Agnes Kathrine Lie
Affiliations
Comparative Study

Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia

Ameli Tropé et al. J Clin Microbiol. 2009 Aug.

Abstract

In the present study we investigated the cross-sectional positivity for DNA and E6/E7 mRNA from high-risk human papillomavirus (HPV) types in 643 women with high-grade cervical neoplasia (135 cases of cervical intraepithelial neoplasia grade 2 [CIN2], 495 cases of CIN3/adenocarcinoma in situ [ACIS], and 13 cases of invasive carcinoma) and in 736 women with normal cytology by using the Amplicor and PreTect HPV-Proofer assays. In addition, genotyping was performed using Linear Array for women with normal cytology and a positive HPV test and in all women with histologically confirmed CIN2+. In women with normal cytology, 8.3% (61/736) were Amplicor positive and 3.3% (24/736) were PreTect HPV-Proofer positive (P < 0.001). Concordant results between the Amplicor and PreTect HPV-Proofer tests were present in 90.3% (665/736). In women with CIN2+ lesions 96.4% (620/643) were positive by Amplicor, 98.4% (633/643) by linear array, and 64.1% (412/643) by PreTect HPV-Proofer. Concordant results for the three HPV assays were present in 63.8%. The genotype profile detected by linear array and PreTect HPV-Proofer showed substantial agreement for HPV types 16, 18, 33, and 45. HPV type 16 and/or 18 was detected in 58.8% (378/643) of the women with high-grade neoplasia. Detection of E6/E7 mRNA by PreTect HPV-Proofer increased with severity of the cervical lesion. Detection of HPV DNA, however, was not associated with histology grade. In conclusion, the detection of HPV varied according to the assay used, and the concordance between the tests was poor. Our results indicate that mRNA testing may be a biomarker for progression of cervical neoplasia, but the optimal genotype mix remains to be determined.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Distribution of genotypes in positive tests among 643 women with CIN2+ detected by linear array. *, probably high-risk HPV genotype (25, IS 39, 53,66, 68, 73, and 82); **, HPV low-risk genotype (6, 11, 40, 42, 54, 61, 70, 72, 81, and CP 6108) or unclassified genotype (55, 62, 64, 67, 69, 71, 83, and 84).
See this image and copyright information in PMC

References

    1. Armed Forces Institute of Pathology. 1992. Tumors of the cervix, vulva and vagina, p. 37-128. Armed Forces Institute of Pathology, Washington, DC.
    1. Bulkmans, N. W., J. Berkhof, L. Rozendaal, F. J. van Kemenade, A. J. Boeke, S. Bulk, F. J. Voorhorst, R. H. Verheijen, K. van Groningen, M. E. Boon, W. Ruitinga, M. van Ballegooijen, P. J. Snijders, and C. J. Meijer. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 3701764-1772. - PubMed
    1. Bulkmans, N. W. J., L. Rozendaal, P. J. F. Snijders, F. J. Voorhorst, A. J. P. Boeke, G. R. J. Zandwijken, F. J. van Kemenade, R. H. M. Verheijen, K. V. Groningen, M. E. Boon, H. J. F. Keuning, B. M. Van, A. J. C. Van Den Brule, and C. J. L. M. Meijer. 2004. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 11094-101. - PubMed
    1. Castle, P. E., J. Dockter, C. Giachetti, F. A. R. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk. 2007. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res. 132599-2605. - PubMed
    1. Cuzick, J., C. Clavel, K.-U. Petry, C. J. L. M. Meijer, H. Hoyer, S. Ratnam, A. Szarewski, P. Birembaut, S. Kulasingam, P. Sasieni, and T. Iftner. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 1191095-1101. - PubMed

Publication types

MeSH terms